MICAD lists 824 imaging, contrast agents

The Molecular Imaging and Contrast Agent Database (MICAD), developed by the National Center for Biotechnology Information at the National Institutes of Health, has added 10 new imaging agents. The MICAD staff had created the Molecular Imaging Probes and Contrast Agents List by screening the PubMed/MedLine databases and other appropriate sources of such information and currently lists 824 agents.

The new PET agents are:
  • 124I-cG250 and 89Zr-Df-cG250 which both targets carbonic anhydrase IX.

The new SPECT agents are:
  • [111In]Anti-uPAR peptide which targets urokinase-type plasminogen activator receptor (uPAR);
  • [99mTc/188Re]DPA-alendronate which targets Farnesyl disphosphate synthas; and
  • 99mTc-NC100692 which targets integrin alphavbeta3.

The new MRI agent is:
  • [1-13C]KIC which targets branched chain amino acid transferase.

The new optical agents are:
  • GB117 and GB113 which both targets cysteine cathepsin; and
  • IntegriSense which targets integrins alphavbeta3/alphavbeta5.

The new multimodality agent is:
  • 99mTc-DTPA-SPION-LBA which targets asialoglycoprotein receptors.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.